For More Videos Like this Subscribe to OncologyTube eNewsletter: [ Ссылка ]
Improved PFS in treatment of multiple myeloma, a multi-clonal disease, by incorporating Isatuximab into the VRD regimen. Dr. Zandra Klippel, MD - Global Product Head of Isatuximab at SANOFI discusses how targeting multiple mechanisms of action can lead to significantly better outcomes for patients.
🔬 Key Highlights:
Mechanism of Action: The addition of Isatuximab to VRD enhances both depth of response and progression-free survival (PFS), with promising trends in overall survival (OS).
Study Results: Early targeting with diverse mechanisms may achieve these long-term effects, especially in transplant-ineligible patients.
Patient Benefits: The study offers new treatment opportunities for this patient population, demonstrating the safety and benefits of the Isatuximab addition.
Watch now to understand the potential of this innovative approach in improving treatment outcomes for multiple myeloma patients! Don't forget to like, share, and subscribe for more updates on the latest in cancer research and treatment.
#MultipleMyeloma #Isatuximab #VRd #CancerResearch #Oncology #ClinicalTrials #ASCO2024 #OncologyTube #ASCO24
